Abstract: The present invention relates to the use of caprylic and capric triglycerides, a combination of caprylic and capric triglycerides and melatonin or a derivative thereof or a composition containing the caprylic and capric triglycerides alone or in combination with melatonin or a derivative thereof for the treatment of a disease or condition mediated by a filaggrin or collagen deficiency.

Abstract: It relates to a combination comprising a) rhamnose or a rhamnose-rich polysaccharide; b) a film-forming agent; and c) one or more further active agents selected from: i) a hyaluronic acid derivative selected from the group consisting of hyaluronic acid, a pharmaceutically or cosmetically acceptable salt thereof, and a cationized hyaluronic acid, ii) a silanol compound, and iii) an extract of Pistacia lentiscus; for use in the treatment and/or prevention of fungal infections in human beings. It also relates to this combination per se, and to pharmaceutical or cosmetic topical nail composition containing it.

Abstract: It relates to a rhamnose or a rhamnose-rich polysaccharide for use in the treatment and/or prevention of fungal infections in human beings. It also relates to a combination of rhamnose or a rhamnose-rich polysaccharide and a further antifungal agent for use in the treatment and/or prevention of fungal infections in human beings. It also relates to pharmaceutical or cosmetic composition comprising an effective amount of rhamnose or a rhamnose-rich polysaccharide for use in the treatment and/or prevention of fungal infections in human beings.

Abstract: The present invention relates to the use of photolyase enzymes to reduce or improve subclinical skin field cancerization associated with actinic keratosis or non-melanoma skin cancer (NMSC) and methods for the therapeutic treatment of subclinical field cancerization associated with actinic keratosis and/or non-melanoma skin cancer (NMSC).

Abstract: The present invention relates to the use of photolyase enzymes to reduce or improve subclinical skin field cancerization associated with actinic keratosis or non-melanoma skin cancer (NMSC) and methods for the therapeutic treatment of subclinical field cancerization associated with actinic keratosis and/or non-melanoma skin cancer (NMSC).

Abstract: It comprises an inhibitor peptide of TGF-?1 for use in preventive or therapeutic treatment of skin tumors at early stages, in which the peptide is disitertide or a derivate thereof, and a pharmaceutical composition that comprises a therapeutically effective amount of the peptide.

Abstract: The present invention refers to a combination of at least 2 UV-absorbing active substances (A) and (B), wherein the UV-absorbing active substance (A) is at least one heptaazaphenalene compound of the general formula (I), which is defined in the description and the UV-ab-sorbing active substance (B) is at least one compound which has its ab-sorption maximum ?maX(B) in the range of UV-A or UV-B radiation.

Abstract: The present invention relates to new pyrrolyltriazine derivatives of general formula (I) together with method for obtaining them. The physico-chemical properties of said compounds allow them to be used as absorbents of UV radiation.

Abstract: The present invention relates to new heptaazaphenalene derivatives of general Formula (I) and to methods for obtaining them. The physicochemical properties of said compounds allow them to be used as UV radiation absorbents.